Robert Barnes appointed as new CEO of Turquoise

* New CEO will help further develop Turquoise’s growing equities platform
* Brings wealth of industry and market expertise to the role
* Robert Barnes expected to take up position in coming weeks

Turquoise, the pan-European MTF, today announces the appointment of Dr Robert Barnes as its new CEO. Dr Barnes has extensive industry experience and market knowledge having formerly been CEO of UBS MTF and a Managing Director, Equities, at UBS. He is a well-regarded industry expert on market structures, having served as Chairman, 2004-2009, of the Securities Trading Committee of the London Investment Banking Association and participated on a wide range of key advisory and policy groups within the financial services sector.

Robert holds a PhD from Cambridge University and a BA from Harvard.

Subject to final FCA approval, Dr Barnes is expected to take up his new role in the coming weeks, replacing current CEO, Natan Tiefenbrun who will be leaving the company.

David Lester, Chairman of Turquoise Holdings, said: “I am delighted to welcome Robert as the new CEO of Turquoise. Robert is a highly regarded senior executive, with extensive industry and market experience and expertise. His skills and knowledge will be of immense value to Turquoise and to the wider Group. I very much look forward to working with him as we continue to grow and develop the Turquoise business.

“I would also like to thank Natan for his contribution to the business’ development in recent years and wish him well for the future.”

- Ends -


Notes to editors:

About London Stock Exchange Group:

London Stock Exchange Group (LSE.L) is a diversified international exchange Group that sits at the heart of the world’s financial community. The Group can trace its history back to 1801.

The Group operates a broad range of international equity, bond and derivatives markets, including London Stock Exchange; Borsa Italiana; MTS, Europe’s leading fixed income market; and the pan-European MTF, Turquoise. Through its markets, the Group offers international business, and investors, unrivalled access to Europe’s capital markets.

Post trade and risk management services are a significant part of the Group’s business operations. LSEG operates CC&G, the Rome headquartered CCP and Monte Titoli, the significant European settlement business, selected as a first wave T2S participant. The Group is also a majority owner of leading multi-asset global CCP, LCH.Clearnet.

The Group offers its customers an extensive range of real-time and reference data products, including Sedol, UnaVista, Proquote and RNS, as well as access to over 200,000 international equity, bond and alternative asset class indices, through LSEG’s world leading index provider, FTSE.

London Stock Exchange Group is also a leading developer of high performance trading platforms and capital markets software. In addition to the Group’s own markets, over 30 other organisations and exchanges around the world use the Group’s MillenniumIT trading, surveillance and post trade technology.

Headquartered in London, United Kingdom with significant operations in Italy, France, North America and Sri Lanka, the Group employs approximately 2,800 people.

Further information on London Stock Exchange Group can be found at: www.lseg.com

Dr Robert Barnes – Biography

Employment
2013
Anopolis - Founder & Managing Director
Advising development of financial centres worldwide by partnering with stakeholders and navigating innovation and best practice to promote liquidity and new business.

1994 - 2013 UBS - Managing Director since 2005
2010 – 2013 CEO, UBS MTF
2009 – 2013 Global Equities Management
2006 – 2009 Equities Distribution Global Products, ETD
1994 – 2006 Various, including positions in Equities, Risk Arbitrage, CEO Management Office, E-commerce

Other current positions
Dr Barnes currently holds a number of other senior advisory positions, including:
2013 NetOTC, NED
2013 BIPB, NED
2012 TheCityUK Chairman, Turkey Advisory Group
2010 CISI, NED and Trustee

Education & professional qualifications
2010 Chartered Fellow of the Chartered Institute for Securities & Investment (CISI)
1994 Cambridge PhD, Biotechnology
1989 Harvard BA, Biochemical Sciences